#NASDAQ #Hong Kong #Initial Public Offering #Charming Medical

Charming Medical Limited IPO Announcement

Overview of Offering
Charming Medical Limited, a company specializing in Traditional Chinese Medicine (TCM), has announced its initial public offering (IPO) of 1,600,000 Class A ordinary shares priced at $4.00 per share. This event marks a significant step for the Hong Kong-based company as it prepares to list its shares on the Nasdaq Capital Market.

Details of the Offering
The Class A Ordinary Shares are set to commence trading under the ticker symbol MCTA on October 21, 2025. The closing of the offering is expected to occur on or about October 22, 2025, pending the satisfaction of customary closing conditions. The gross proceeds from the offering are anticipated to be around $6.4 million, before any deductions for underwriting costs and expenses. Additionally, the company has granted underwriters the option to purchase an additional 240,000 shares, which could raise the total proceeds to approximately $7.36 million if fully exercised.

Utilization of Funds
Charming Medical Limited plans to allocate the net proceeds from this IPO towards expanding its business operations and geographic footprint, pursuing strategic investments and acquisitions, investing in research and development, and managing general corporate expenses.

Underwriters and Legal Counsel
The offering is being conducted on a firm commitment basis with Cathay Securities, Inc. acting as the lead underwriter. Various law firms, including Ortoli Rosenstadt LLP and Harney Westwood Riegels, are providing legal counsel in the U.S., British Virgin Islands, and Hong Kong respectively.

Company Background
Charming Medical Limited integrates principles of Traditional Chinese Medicine with modern technological advancements to enhance well-being and quality of life. With four wellness centers in Hong Kong, the company specializes in treatments such as womb-warming therapy and pelvic detox therapy, focusing particularly on women’s health issues like hormonal imbalances and postpartum recovery.

Under the “Beauty Lab” brand, Charming Medical develops and markets TCM-inspired beauty products, including supplements and skincare items aimed at improving women’s health and vitality. The company also supports its mission by providing training and franchise opportunities to extend its wellness philosophy across the industry.

Forward-Looking Statements
Charming Medical Limited warns that forward-looking statements made in relation to the IPO may be subject to risks and uncertainties. Investors are advised to read the prospectus and other relevant documents filed with the SEC, which provide comprehensive insights into the company's operations and financial future.

For further details, you can visit their website at Charming Medical.

Conclusion
This IPO stands as a pivotal milestone for Charming Medical Limited, signaling its readiness to grow in the public sphere and attract a broader investor base. With a unique product offering rooted in TCM, the company aims to carve a niche within the wellness and healthcare industry as it moves forward post-IPO.